Is China SXT Stock a Good Investment?
China SXT Investment Advice | SXTC |
- Examine China SXT's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research China SXT's leadership team and their track record. Good management can help China SXT navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Personal Care Products space and any emerging trends that could impact China SXT's business and its evolving consumer preferences.
- Compare China SXT's performance and market position to its competitors. Analyze how China SXT is positioned in terms of product offerings, innovation, and market share.
- Check if China SXT pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about China SXT's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in China SXT Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if China SXT Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine China SXT Stock
Researching China SXT's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. China SXT Pharmaceuticals recorded a loss per share of 28.58. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 5th of October 2023.
To determine if China SXT is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding China SXT's research are outlined below:
| China SXT is way too risky over 90 days horizon | |
| China SXT appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 1.93 M. Net Loss for the year was (3.1 M) with profit before overhead, payroll, taxes, and interest of 553.97 K. | |
| China SXT Pharmaceuticals currently holds about 15.52 M in cash with (1.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| China SXT has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange - TipRanks |
China SXT uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in China SXT Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to China SXT's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 30th of October 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View |
Know China SXT's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as China SXT is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading China SXT Pharmaceuticals backward and forwards among themselves. China SXT's institutional investor refers to the entity that pools money to purchase China SXT's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of Montreal | 2024-12-31 | 10 K | Bmo Capital Markets Corp. | 2024-12-31 | 10 K | Ubs Group Ag | 2024-12-31 | 8.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Gsa Capital Partners Llp | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Baader Bank Inc | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
China SXT's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 38.12 M.Market Cap |
|
China SXT's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.15) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.13) | (0.15) | |
| Return On Equity | (0.26) | (0.24) |
Determining China SXT's profitability involves analyzing its financial statements and using various financial metrics to determine if China SXT is a good buy. For example, gross profit margin measures China SXT's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of China SXT's profitability and make more informed investment decisions.
Please note, the presentation of China SXT's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, China SXT's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of China SXT's management manipulating its earnings.
Evaluate China SXT's management efficiency
China SXT Pharmaceuticals has return on total asset (ROA) of (0.0497) % which means that it has lost $0.0497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2165) %, meaning that it created substantial loss on money invested by shareholders. China SXT's management efficiency ratios could be used to measure how well China SXT manages its routine affairs as well as how well it operates its assets and liabilities. As of March 27, 2025, Return On Tangible Assets is expected to decline to -0.15. The current year's Return On Capital Employed is expected to grow to -0.19. At present, China SXT's Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 11.4 M, whereas Total Assets are forecasted to decline to about 21.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 18.47 | 17.55 | |
| Tangible Book Value Per Share | 18.44 | 17.52 | |
| Enterprise Value Over EBITDA | (1.03) | (0.97) | |
| Price Book Value Ratio | 0.95 | 0.90 | |
| Enterprise Value Multiple | (1.03) | (0.97) | |
| Price Fair Value | 0.95 | 0.90 | |
| Enterprise Value | 2.4 M | 2.3 M |
Understanding the operational decisions made by China SXT management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.121 |
Basic technical analysis of China Stock
As of the 27th of March, China SXT shows the Risk Adjusted Performance of 0.0647, downside deviation of 9.94, and Mean Deviation of 8.28. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of China SXT, as well as the relationship between them.China SXT's Outstanding Corporate Bonds
China SXT issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. China SXT Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most China bonds can be classified according to their maturity, which is the date when China SXT Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand China SXT's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing China SXT's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0647 | |||
| Market Risk Adjusted Performance | 0.7402 | |||
| Mean Deviation | 8.28 | |||
| Semi Deviation | 9.09 | |||
| Downside Deviation | 9.94 | |||
| Coefficient Of Variation | 1531.29 | |||
| Standard Deviation | 19.92 | |||
| Variance | 396.71 | |||
| Information Ratio | 0.0649 | |||
| Jensen Alpha | 1.3 | |||
| Total Risk Alpha | 1.35 | |||
| Sortino Ratio | 0.1301 | |||
| Treynor Ratio | 0.7302 | |||
| Maximum Drawdown | 180.99 | |||
| Value At Risk | (10.61) | |||
| Potential Upside | 12.64 | |||
| Downside Variance | 98.75 | |||
| Semi Variance | 82.63 | |||
| Expected Short fall | (10.97) | |||
| Skewness | 5.82 | |||
| Kurtosis | 43.21 |
| Risk Adjusted Performance | 0.0647 | |||
| Market Risk Adjusted Performance | 0.7402 | |||
| Mean Deviation | 8.28 | |||
| Semi Deviation | 9.09 | |||
| Downside Deviation | 9.94 | |||
| Coefficient Of Variation | 1531.29 | |||
| Standard Deviation | 19.92 | |||
| Variance | 396.71 | |||
| Information Ratio | 0.0649 | |||
| Jensen Alpha | 1.3 | |||
| Total Risk Alpha | 1.35 | |||
| Sortino Ratio | 0.1301 | |||
| Treynor Ratio | 0.7302 | |||
| Maximum Drawdown | 180.99 | |||
| Value At Risk | (10.61) | |||
| Potential Upside | 12.64 | |||
| Downside Variance | 98.75 | |||
| Semi Variance | 82.63 | |||
| Expected Short fall | (10.97) | |||
| Skewness | 5.82 | |||
| Kurtosis | 43.21 |
Consider China SXT's intraday indicators
China SXT intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of China SXT stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
China SXT Corporate Filings
6K | 19th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 21st of January 2025 Other Reports | ViewVerify | |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify |
China Stock media impact
Far too much social signal, news, headlines, and media speculation about China SXT that are available to investors today. That information is available publicly through China media outlets and privately through word of mouth or via China internal channels. However, regardless of the origin, that massive amount of China data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of China SXT news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of China SXT relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to China SXT's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive China SXT alpha.
China SXT Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards China SXT can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (28.58) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between China SXT's value and its price, as these two are different measures arrived at by various means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.